This article is more than 5 years old. Information may no longer be current.

Study: TTT helps prevent CNV visual loss at 12 months

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

STOCKHOLM, Sweden — Transpupillary thermotherapy generally prevented moderate and severe visual loss at 12 months in patients with occult, but no classic, choroidal neovascularization in a preliminary trial.

Peep V. Algvere, MD, PhD and others here at St. Erik’s Eye Hospital enrolled 49 patients with occult choroidal neovascularization (CNV) and 64 patients with occult with minimally classic CNV. Lesions were classified as less than 3 mm or more than 3 mm.

Average baseline acuity was 0.20, improving to 0.12 at 6 months and remaining stable at the 12-month follow-up. Acuity improved in nine eyes, remained unchanged in 46 and deteriorated in 58.

These results compare favorably with the natural history of the disease, the researchers said.

The most common complications in the 46 eyes that lost acuity were subretinal progressive fibrosis and atrophy of the retinal pigment epithelium.

The study is published in the April issue of Acta Ophthalmologica Scandinavica.